Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: A ten-year single institution experience

Oncology

Volumn 76, Issue 6, 2009, Pages 413-419

  Turrini, Olivier ^a   Viret, Frédéric ^a   Moureau Zabotto, Laurence ^a   Guiramand, Jérome ^a   Moutardier, Vincent ^a   Lelong, Bernard ^a   De Chaisemartin, Cécile ^a   Giovannini, Marc ^a   Delpero, Jean Robert ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Chemoradiation; Neoadjuvant; Pancreatic adenocarcinoma; Pancreatic cancer

Indexed keywords

CISPLATIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; FEVER; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SKIN DISEASE; VOMITING; WEIGHT REDUCTION; ADENOCARCINOMA; ADJUVANT THERAPY; DISEASE FREE SURVIVAL; FOLLOW UP; METHODOLOGY; PANCREAS; PANCREAS TUMOR; RECURRENT DISEASE; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; NEOADJUVANT THERAPY; PANCREAS; PANCREATIC NEOPLASMS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 65449156920     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000215928     Document Type: Article

References (30)

1. Traverso LW: Pancreatic cancer: surgery alone is not sufficient. Surg Endosc 2006;20(suppl 2): S446-S449.
2. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized control led trial. JAMA 2007;297:267-277.
3. Aloia TE, Lee JE, Vauthey JN, et al: Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J Am Coll Surg 2007;204:347-355.
4. Snady H, Bruckner H, Cooperman A, et al: Survival advantage of combined chemora-diotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000;89:314-327.
5. Coia L, Hoffman J, Scher R, et al: Preopera-tive chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys 1994;30:161-167.
6. Moutardier V, Turrini O, Huiart L, et al: A reappraisal of preoperative chemoradiation for localized pancreatic head ductal adeno-carcinoma in a 5-year single-institution experience. J Gastrointest Surg 2004;8:502-510.
7. Moutardier V, Giovannini M, Lelong B, et al: A phase II single institutional experience with preoperative radiochemotherapy in pancreatic adenocarcinoma. Eur J Surg Oncol 2002;28:531-539.
8. Wayne JD, Abdalla EK, Wolff RA, et al: Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist 2002;7:34-45.
9. Evans DB, Wolff RA, Crane CH: Neoadju-vant strategies for pancreatic cancer. Oncology (Williston Park) 2001;15:727-737.
10. Breslin TM, Hess KR, Harbison DB, et al: Neoadjuvant chemoradiotherapy for adeno-carcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001;8:123-132.
11. Griffin JF, Smalley SR, Jewell W, et al: Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990;66:56-61.
12. Kayahara M, Nagakawa T, Ueno K, et al: An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 1993;72:2118-2123.
13. Nitecki SS, Sarr MG, Colby TV, et al: Long-term survival after resection for ductal ade-nocarcinoma of the pancreas. Is it really improving? Ann Surg 1995;221:59-66.
14. Sperti C, Pasquali C, Piccoli A, et al: Recurrence after resection for ductal adenocarci-noma of the pancreas. World J Surg 1997;21:195-200.
15. Spitz FR, Abbruzzese JL, Lee JE, et al: Preop-erative and postoperative chemoradiation strategies in patients treated with pancreati-coduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997;15:928-937.
16. Hoffman JP, Lipsitz S, Pisansky T, et al: Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, re-sectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998;16:317-323.
17. Evans DB, Rich TA, Byrd DR, et al: Preop-erative chemoradiation and pancreaticodu-odenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127:1335-1339.
18. White RR, Hurwitz HI, Morse MA, et al: Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001;8:758-765.
19. Mehta VK, Fisher G, Ford JA, et al: Preop-erative chemoradiation for marginally re-sectable adenocarcinoma of the pancreas. J Gastrointest Surg 2001;5:27-35.
20. Evans DB, Varadhachary GR, Crane CH, et al: Preoperative gemcitabine-based chemo-radiation for patients with resectable adeno-carcinoma of the pancreatic head. J Clin Oncol 2008;26:3496-3502.
21. Varadhachary GR, Wolff RA, Crane CH, et al: Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradia-tion for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:3487-3495.
22. Magnin V, Moutardier V, Giova nnini MH, et al: Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys 2003;55:1300-1304.
23. Pisters PW, Hudec WA, Lee JE, et al: Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol 2000;18:860-867.
24. Evans DB;for The Multidisciplinary Pancreatic Cancer Study Group: Resectable pancreatic cancer: the role for neoadjuvant/preoperative therapy. HPB (Oxford) 2006;8:365-368.
25. Turrini O, Viret F, Moureau-Zabotto L, et al: A modified Dworak classification applied to pancreatic adenocarcinoma: a useful prognostic factor. Bull Cancer 2007;94:897-901.
26. Sasson AR, Wetherington RW, Hoffman JP, et al: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastroin-test Cancer 2003;34:121-128.
27. White RR, Xie HB, Gottfried MR, et al: Significance of histological response to preop-erative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol 2005;12:212-221.
28. Ferrone CR, Finkelstein DM, Thayer SP, et al: Perioperative CA19-9levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897-2902.
29. Maithel SK, Maloney S, Winston C, et al: Preoperative CA 19-9and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 2008;15:3512-3520.
30. Esposito I, Kleeff J, Bergmann F, et al: Most pancreatic cancer resections are R1resections. Ann Surg Oncol 2008;15:1651-1660.